U.S. Non-alcoholic Steatohepatitis Clinical Trials Market Size & Outlook
Related Markets
U.S. non-alcoholic steatohepatitis clinical trials market highlights
- The U.S. non-alcoholic steatohepatitis clinical trials market generated a revenue of USD 1,275.3 million in 2024 and is expected to reach USD 1,761.6 million by 2030.
- The U.S. market is expected to grow at a CAGR of 5.8% from 2025 to 2030.
- In terms of segment, phase iii was the largest revenue generating phase in 2024.
- Phase I is the most lucrative phase segment registering the fastest growth during the forecast period.
Non-alcoholic steatohepatitis clinical trials market data book summary
| Market revenue in 2024 | USD 1,275.3 million |
| Market revenue in 2030 | USD 1,761.6 million |
| Growth rate | 5.8% (CAGR from 2025 to 2030) |
| Largest segment | Phase iii |
| Fastest growing segment | Phase I |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Phase I, Phase II, Phase III, Phase IV |
| Key market players worldwide | Pfizer Inc, Novartis AG ADR, Icon PLC, Labcorp Holdings Inc, Allergan, Zydus Lifesciences, Takeda Pharmaceutical Co Ltd, Eli Lilly and Co, Novo Nordisk A/S ADR, Gilead Sciences Inc, GlaxoSmithKline, Arrowhead Pharmaceuticals Inc |
Other key industry trends
- In terms of revenue, U.S. accounted for 43.6% of the global non-alcoholic steatohepatitis clinical trials market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. non-alcoholic steatohepatitis clinical trials market is projected to lead the regional market in terms of revenue in 2030.
- U.S. is the fastest growing regional market in North America and is projected to reach USD 1,761.6 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Non-alcoholic Steatohepatitis Clinical Trials Market Scope
Non-alcoholic Steatohepatitis Clinical Trials Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Arrowhead Pharmaceuticals Inc | View profile | 525 | 177 E. Colorado Boulevard, Suite 700, Pasadena, CA, United States, 91105 | https://www.arrowheadpharma.com |
| Zydus Lifesciences | View profile | 10001+ | Ahmedabad, Gujarat, India, Asia | https://zyduslife.com/ |
| GlaxoSmithKline | View profile | 10001+ | London, England, United Kingdom, Europe | http://www.gsk.com |
| Takeda Pharmaceutical Co Ltd | View profile | 49095 | 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan, 103-8668 | https://www.takeda.com |
| Gilead Sciences Inc | View profile | 18000 | 333 Lakeside Drive, Foster, CA, United States, 94404 | https://www.gilead.com |
| Icon PLC | View profile | 41150 | South County Business Park, Leopardstown, Dublin, Ireland, D18 X5R3 | https://www.iconplc.com |
| Novo Nordisk A/S ADR | View profile | 66015 | Novo Alle 1, Bagsvaerd, Denmark, 2880 | https://www.novonordisk.com |
| Eli Lilly and Co | View profile | 43000 | Lilly Corporate Center, Indianapolis, IN, United States, 46285 | https://www.lilly.com |
| Allergan | View profile | 10001+ | Madison, Wisconsin, United States, North America | http://www.allergan.com |
| Labcorp Holdings Inc | View profile | 67000 | 358 South Main Street, Burlington, NC, United States, 27215 | https://www.labcorp.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
U.S. non-alcoholic steatohepatitis clinical trials market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to non-alcoholic steatohepatitis clinical trials market will help companies and investors design strategic landscapes.
Phase iii was the largest segment with a revenue share of 56.78% in 2024. Horizon Databook has segmented the U.S. non-alcoholic steatohepatitis clinical trials market based on phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2018 to 2030.
- U.S. Non-alcoholic Steatohepatitis Clinical Trials Phase Outlook (Revenue, USD Million, 2018-2030)
- Phase I
- Phase II
- Phase III
- Phase IV
- U.S. Non-alcoholic Steatohepatitis Clinical Trials Study Design Outlook (Revenue, USD Million, 2018-2030)
- Interventional
- Observational
- Expanded Access
Reasons to subscribe to U.S. non-alcoholic steatohepatitis clinical trials market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. non-alcoholic steatohepatitis clinical trials market databook
-
Our clientele includes a mix of non-alcoholic steatohepatitis clinical trials market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. non-alcoholic steatohepatitis clinical trials market, including forecasts for subscribers. This country databook contains high-level insights into U.S. non-alcoholic steatohepatitis clinical trials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. non-alcoholic steatohepatitis clinical trials market size, by phase, 2018-2030 (US$M)
U.S. Non-alcoholic Steatohepatitis Clinical Trials Market Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
